Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ)
CNY 3.77
(3.86%)
CNY 3.77
(3.86%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.62 Billion CNY | -2.75% |
| 2022 | 3.72 Billion CNY | -26.8% |
| 2021 | 5.09 Billion CNY | 5.07% |
| 2020 | 4.84 Billion CNY | 10.21% |
| 2019 | 4.39 Billion CNY | 28.63% |
| 2018 | 3.41 Billion CNY | -8.36% |
| 2017 | 3.73 Billion CNY | 13.66% |
| 2016 | 3.28 Billion CNY | 45.13% |
| 2015 | 2.26 Billion CNY | 17.85% |
| 2014 | 1.91 Billion CNY | 15.74% |
| 2013 | 1.65 Billion CNY | 19.57% |
| 2012 | 1.38 Billion CNY | 8.25% |
| 2011 | 1.28 Billion CNY | 37.73% |
| 2010 | 930.32 Million CNY | 75.97% |
| 2009 | 528.69 Million CNY | 14.67% |
| 2008 | 461.05 Million CNY | 46.25% |
| 2007 | 315.26 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 782.13 Million CNY | -7.14% |
| 2024 Q2 | 724.47 Million CNY | -7.37% |
| 2024 Q3 | 762.82 Million CNY | 5.29% |
| 2023 Q3 | 850.85 Million CNY | -13.31% |
| 2023 Q2 | 981.47 Million CNY | 3.16% |
| 2023 Q4 | 842.27 Million CNY | -1.01% |
| 2023 Q1 | 951.41 Million CNY | 2.37% |
| 2023 FY | 3.62 Billion CNY | -2.75% |
| 2022 Q1 | 888.83 Million CNY | -14.65% |
| 2022 Q2 | 836.79 Million CNY | -5.85% |
| 2022 FY | 3.72 Billion CNY | -26.8% |
| 2022 Q4 | 929.39 Million CNY | -13.43% |
| 2022 Q3 | 1.07 Billion CNY | 28.29% |
| 2021 Q1 | 1.29 Billion CNY | -12.34% |
| 2021 Q3 | 1.4 Billion CNY | 3.89% |
| 2021 FY | 5.09 Billion CNY | 5.07% |
| 2021 Q4 | 1.04 Billion CNY | -25.93% |
| 2021 Q2 | 1.35 Billion CNY | 4.64% |
| 2020 FY | 4.84 Billion CNY | 10.21% |
| 2020 Q2 | 1.02 Billion CNY | 8.94% |
| 2020 Q1 | 945.08 Million CNY | -26.21% |
| 2020 Q3 | 1.39 Billion CNY | 35.77% |
| 2020 Q4 | 1.47 Billion CNY | 5.55% |
| 2019 Q1 | 898.7 Million CNY | -13.38% |
| 2019 FY | 4.39 Billion CNY | 28.63% |
| 2019 Q4 | 1.28 Billion CNY | 11.82% |
| 2019 Q3 | 1.14 Billion CNY | 6.67% |
| 2019 Q2 | 1.07 Billion CNY | 19.48% |
| 2018 Q3 | 762.1 Million CNY | -10.08% |
| 2018 Q1 | 772.62 Million CNY | -43.34% |
| 2018 Q4 | 1.03 Billion CNY | 36.14% |
| 2018 Q2 | 847.49 Million CNY | 9.69% |
| 2018 FY | 3.41 Billion CNY | -8.36% |
| 2017 Q4 | 1.36 Billion CNY | 80.79% |
| 2017 Q2 | 895.62 Million CNY | 24.73% |
| 2017 FY | 3.73 Billion CNY | 13.66% |
| 2017 Q1 | 718.04 Million CNY | -46.19% |
| 2017 Q3 | 754.26 Million CNY | -15.78% |
| 2016 Q4 | 1.33 Billion CNY | 61.04% |
| 2016 Q1 | 496.59 Million CNY | -32.84% |
| 2016 FY | 3.28 Billion CNY | 45.13% |
| 2016 Q2 | 623.4 Million CNY | 25.54% |
| 2016 Q3 | 828.61 Million CNY | 32.92% |
| 2015 Q2 | 563.37 Million CNY | 29.42% |
| 2015 FY | 2.26 Billion CNY | 17.85% |
| 2015 Q4 | 739.41 Million CNY | 41.11% |
| 2015 Q3 | 523.99 Million CNY | -6.99% |
| 2015 Q1 | 435.31 Million CNY | -32.25% |
| 2014 Q2 | 374.58 Million CNY | 8.63% |
| 2014 Q4 | 642.49 Million CNY | 15.23% |
| 2014 Q3 | 557.57 Million CNY | 48.85% |
| 2014 FY | 1.91 Billion CNY | 15.74% |
| 2014 Q1 | 344.82 Million CNY | -12.88% |
| 2013 Q2 | 358.71 Million CNY | 16.28% |
| 2013 Q3 | 595.47 Million CNY | 66.0% |
| 2013 Q4 | 395.79 Million CNY | -33.53% |
| 2013 FY | 1.65 Billion CNY | 19.57% |
| 2013 Q1 | 308.5 Million CNY | -16.04% |
| 2012 Q2 | 289.19 Million CNY | -6.0% |
| 2012 Q1 | 307.66 Million CNY | 28.22% |
| 2012 FY | 1.38 Billion CNY | 8.25% |
| 2012 Q4 | 367.44 Million CNY | -13.08% |
| 2012 Q3 | 422.75 Million CNY | 46.18% |
| 2011 Q4 | 239.94 Million CNY | -49.73% |
| 2011 FY | 1.28 Billion CNY | 37.73% |
| 2011 Q1 | 273.12 Million CNY | -4.35% |
| 2011 Q2 | 290.95 Million CNY | 6.53% |
| 2011 Q3 | 477.34 Million CNY | 64.06% |
| 2010 Q4 | 285.53 Million CNY | -9.55% |
| 2010 FY | 930.32 Million CNY | 75.97% |
| 2010 Q1 | 129.83 Million CNY | -10.58% |
| 2010 Q2 | 199.27 Million CNY | 53.48% |
| 2010 Q3 | 315.68 Million CNY | 58.42% |
| 2009 FY | 528.69 Million CNY | 14.67% |
| 2009 Q4 | 145.19 Million CNY | -9.83% |
| 2009 Q3 | 161.01 Million CNY | 0.0% |
| 2008 FY | 461.05 Million CNY | 46.25% |
| 2007 FY | 315.26 Million CNY | 0.0% |